Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Strangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep. The company was incorporated in 1983 and is based in Hägersten, Sweden.
Frequently asked questions
What sector does Intervacc AB (IVACC) operate in?
Intervacc AB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Intervacc AB (IVACC) current stock price?
As of the latest data, Intervacc AB stock price is SEK 1.22, with a previous close of SEK 1.20. Intervacc AB gained SEK 0.02 in the last trading session, representing a 1.67% increase.
What is Intervacc AB (IVACC) current market capitalization?
Intervacc AB market cap is approximately 415.79 million.
What is Intervacc AB (IVACC) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.25, and the forward EPS is -SEK 0.24.
What is Intervacc AB (IVACC) EBITDA?
Intervacc AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -18.15 million.
Does Intervacc AB (IVACC) pay dividends?
No. Intervacc AB does not pay a dividend.
How did Intervacc AB (IVACC) perform in its most recent earnings report?
In the last report (March 31, 2026), Intervacc AB posted an EPS surprise of 0% and a revenue surprise of -60.77%.
When is Intervacc AB (IVACC) next earnings report?
Intervacc AB is expected to release its next earnings report on June 30, 2026.
What is Intervacc AB (IVACC) beta (volatility) score?
Intervacc AB has a beta of 0.154, indicating lower volatility than the overall market.
